KC-3259
Methylthioadenosine phosphorylase (MTAP), also known as MSAP, is an enzyme that recycles adenine and methionine after polyamine synthesis. Human MTAP is expressed across many tissues, including epithelial organs, rather than being lung-specific. Homozygous deletion at chromosome 9p21 often accompanies CDKN2A loss in cancers such as lung tumors, mesothelioma and glioma. MTAP loss can increase methylthioadenosine and create vulnerability to inhibition of protein arginine methyltransferase 5 (PRMT5) or methionine adenosyltransferase 2A (MAT2A). This biology has prompted development of biomarker-selected therapies. MRTX1719, also called BMS-986504, is an investigational MTA-cooperative PRMT5 inhibitor with preclinical activity and early clinical responses reported in some MTAP-deleted cancers. These studies concern MTAP-deficient tumors and do not establish clinical efficacy for an MTAP-expressing cell line.
| Catalog Number | KC-3259 |
|---|---|
| Cell Line Name | LU99-MTAP Cell Line |
| NCBI/UniProt Accession Number | NM_002451.4 |
| Clone Number | 1# |
| Host Cell Line | LU99 |
| Description | LU99 cell line stably expressing exogenous human MTAP gene |
| Quantity | One vial of frozen cells (≥2×106 cells) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Freezing Medium | 70% RPMI1640+20% FBS+10% DMSO |
| Propagation Medium | RPMI1640+10%FBS+1 μg/mL Puromycin |
| Selection Marker | Puromycin |
| Morphology | Epithelial-like |
| Subculture | Split at a ratio of 1:10 every 3 days |
| Incubation | 37 °C with 5% CO₂ |
| Storage | Liquid nitrogen immediately upon receiving |
| Doubling Time | Estimated 21–25 hours |
| Mycoplasma Status | Negative |
| In Vivo Validation | NA |